Is CME Group (CME) Overvalued or Undervalued? A Complete Valuation Analysis 2026

The short answer

Short answer: CME Group looks undervalued at current levels. Compared with the recent share price of $286.85, the current DCF output near $509.43 suggests CME Group is about 43.7% undervalued on these cash flow assumptions. CME Group is usually valued on transaction growth, margin durability, and free cash flow rather than on P/E alone. The fair answer comes down to whether payment volume, operating leverage, and cash generation still justify the premium the market is assigning to the network.

Why valuing this kind of financial services company is more complex than it looks

CME Group operates in Financial - Data & Stock Exchanges, where the market often weighs payment volume growth, network effects, and cash generation together.

The reason this matters is simple. Two companies can show similar headline multiples and still deserve very different valuations because their margins, cash conversion, and growth durability are not the same.

The 5 key metrics applied to CME Group

A single ratio rarely tells the whole story. This framework starts with trailing P/E, forward P/E, PEG, EV/EBITDA, and price to sales, then keeps only the metrics that are present and usable for this company.

Trailing P/E

Trailing P/E compares the current share price with the last twelve months of earnings. For CME, the current reading is 25.7x. Shows what the market is paying for CME's recent earnings.

Forward P/E

Forward P/E uses expected earnings instead of trailing earnings. For CME, the current reading is 130.2x. Shows how the market is valuing CME's expected earnings.

PEG ratio

PEG compares the earnings multiple with expected growth. For CME, the current reading is 8.8x. Helps show whether the earnings multiple is being offset by expected growth.

EV/EBITDA

EV/EBITDA compares enterprise value with operating profit before depreciation and amortization. For CME, the current reading is 17.1x. Adds a capital structure aware check on operating valuation.

Price to sales

Price to sales compares market value with revenue. For CME, the current reading is 15.4x. Useful when revenue mix, margins, or future scaling matter as much as near term earnings.

Free cash flow yield

Free cash flow yield compares free cash flow with market value. For CME, the current reading is 4.2%. Shows how much cash CME is generating relative to its market value.

Metric	Current value	What it suggests
Trailing P/E	25.7x	Shows what the market is paying for CME's recent earnings.
Forward P/E	130.2x	Shows how the market is valuing CME's expected earnings.
PEG ratio	8.8x	Helps show whether the earnings multiple is being offset by expected growth.
EV/EBITDA	17.1x	Adds a capital structure aware check on operating valuation.
Price to sales	15.4x	Useful when revenue mix, margins, or future scaling matter as much as near term earnings.
Free cash flow yield	4.2%	Shows how much cash CME is generating relative to its market value.
Gross margin	86.3%	Shows how much of CME's revenue remains after direct costs.
Revenue growth	6.4%	Shows whether CME's top line is still expanding.

The table is a snapshot of the current setup. It is meant to frame the valuation question, not replace the company specific analysis below.

CME Group's valuation breakdown

As of Q2 2026, CME Group traded near $286.85 with a market value near $103.94B.

Metric	Current value	What it suggests
Trailing P/E	25.7x	Shows what the market is paying for CME's recent earnings.
Forward P/E	130.2x	Shows how the market is valuing CME's expected earnings.
PEG ratio	8.8x	Helps show whether the earnings multiple is being offset by expected growth.
EV/EBITDA	17.1x	Adds a capital structure aware check on operating valuation.
Price to sales	15.4x	Useful when revenue mix, margins, or future scaling matter as much as near term earnings.
Free cash flow yield	4.2%	Shows how much cash CME is generating relative to its market value.
Gross margin	86.3%	Shows how much of CME's revenue remains after direct costs.
Revenue growth	6.4%	Shows whether CME's top line is still expanding.

Metrics move with the market and with each earnings update. If a field is missing or stale, it is intentionally left out here rather than guessed.

What the numbers tell us

The first thing to notice with CME is the gap between trailing and forward earnings valuation. Trailing P/E is near 25.7x while forward P/E is near 130.2x, which tells you the market is already underwriting a specific earnings path.

CME's forward P/E is not offering much relief versus the trailing multiple, so the market may still be paying up before the earnings improvement is fully visible.
CME's PEG ratio near 8.8x matters because it tests whether the earnings multiple is being balanced by a credible growth rate.
CME's price to sales multiple near 15.4x needs to be read beside revenue growth near 6.4%, because rich revenue multiples only hold up when growth quality stays intact.

CME Group's competitive position

CME Group's competitive position depends on network reach, transaction volume, and how sticky its payment or financial rails are for customers and partners.

What would make CME Group look cheaper or more expensive?

What would make it look cheaper

CME would look cheaper if the business kept growing while valuation multiples moved lower.
CME would also look more attractive if cash generation improved without the market price rising at the same pace.

What would make it look expensive

CME would look expensive if earnings or revenue expectations softened while the current multiple stayed elevated.
CME would also look expensive if margins weakened but the stock kept the same quality premium.

Financial Services valuation context

CME Group operates in Financial - Data & Stock Exchanges, where the market often weighs payment volume growth, network effects, and cash generation together.

The verdict

CME Group looks priced for a very strong execution path from here. The stock can still work, but future earnings and cash flow need to validate the premium already in the shares. With forward P/E near 130.2x, the market is already making a judgment about the next stage of earnings power.

This is analysis of publicly available market data. It is not financial advice, and it should be read in the context of personal goals, risk tolerance, and time horizon.

Want to run the numbers yourself?

Use TopTier Strategy research tools to review CME's live valuation profile, stock page, and related company analysis.

Analyze CME on TopTier Strategy View CME stock page

Frequently asked questions

Is CME Group stock overvalued in 2026?

Based on the current research read, CME Group looks undervalued in 2026. The main drivers in this read are trailing P/E near 25.7x and forward P/E near 130.2x, gross margin near 86.3%, free cash flow yield near 4.2%. CME Group is usually valued on transaction growth, margin durability, and free cash flow rather than on P/E alone.

Is CME Group a good stock to buy right now?

CME Group may appeal more to investors who think the market is underestimating the current business quality or earnings path, but that still depends on time horizon and risk tolerance.

What is CME Group's fair value?

A fair value estimate depends on the mix of earnings, growth, margins, and cash generation rather than on a single published number. For CME Group, the current read is shaped mainly by trailing P/E near 25.7x and forward P/E near 130.2x, gross margin near 86.3%, free cash flow yield near 4.2%. This article does not publish a stand alone fair value number unless there is a clearly supportable public methodology behind it.

Can you value CME Group just on P/E?

No. CME Group needs to be read through volume growth, margins, cash generation, and business quality as well as P/E.

Where can I analyze CME with current data?

Use the TopTier Strategy research platform at toptierstrategy.com/research to review live valuation, profitability, financial health, shareholder returns, and growth data for CME.

Data source: TopTier Strategy research platform - toptierstrategy.com/research. Data as of 2026-05-08T00:32:19.553280.